Dale Goldhawk, Vice Chair of ADI, takes a personal view on psychosocial dementia research.
It’s a sad fact that, to date, not much in the Alzheimer research world has been considered “groundbreaking”. The development of cholinesterase inhibitors certainly marked some progress but, while those medications can help with symptoms, they bear no resemblance to an effective treatment. And that’s where we are today in 2019. Sure, there have been some research and clinical trials, showing the usual “promising results” but these promises are often modest at best.
To my way of thinking, any breakthroughs will likely come through psychosocial not biomedical research. And when I think of quality of life breakthroughs, one immediately comes to mind.Continue reading “Dementia Research: Where are we now?”